Latham & Watkins Advises the Underwriters in CureVac’s Initial Public Offering

CureVac B.V., a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid, has announced the pricing of its initial public offering of 13,333,333 common shares at an initial public offering price of US$16.00 per common share, for total gross proceeds of approximately $213.3 million. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 1,999,999 common shares at the public offering price, less underwriting discounts and commissions. All of the common shares are being offered by CureVac. The shares are scheduled to begin trading on the Nasdaq Global Market today, August 14, 2020, under the ticker symbol “CVAC.” The offering is expected to close on August 18, 2020, subject to customary closing conditions. 

Latham & Watkins LLP represents the underwriters in the offering with a capital markets team led by New York partner Nathan Ajiashvili and Frankfurt partner Oliver Seiler, with New York associates Adam Johnson and Patrick Maguire and London associate Dominika Kovacicova.